Please login to the form below
prostate cancer
This page shows the latest prostate cancer news and features for those working in and with pharma, biotech and healthcare.
FDA approves Novartis’ Pluvicto for prostate cancer
Novartis has announced that it has received approval from the US Food and Drug Administration (FDA) for Pluvicto for the treatment of adult patients with advanced prostate cancer. ... Prostate cancer is the second leading cause of cancer-related death in
Latest news
-
EIT Health raises awareness on World Cancer Day 2022
early detection of lung and prostate cancer. ... EIT Health supports various cancer programmes and start-ups aiming to improve outcomes for lung and prostate cancer patients, including Stockholm3, OncoWatch and Optellum – three programmes using
-
Gilead to pay $745m for three oncology programmes from Arcus Biosciences
The other programmes are for etrumadenant, a dual adenosine A2a/A2b receptor antagonist in phase 1/2 studies in NSCLC, colon cancer and prostate cancer, and quemliclustat, a small molecule CD73 ... deliver benefit to patients with some of the most
-
AstraZeneca signs for-profit agreements for its COVID-19 vaccine
with paroxysmal nocturnal haemoglobinuria, plus breakthrough therapy designation for Enhertu (trastuzumab deruxtecan) in breast cancer. ... The results include Lynparza in prostate cancer, Imfinzi plus tremelimumab in liver cancer and biliary tract cancer
-
Lynparza significantly delays disease progression as first-line treatment in prostate cancer
New data show AstraZeneca and Merck‘s PARP inhibitor, Lynparza, delayed disease progression as a first-line treatment in advanced prostate cancer. ... Last year, they entered the prostate cancer setting with the approval of Clovis’ Rubraca (rucaparib)
-
Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
Amgen’s BiTEs work by attaching themselves to both a cancer cell and T cell, bringing them together so the body’s immune system can kill the cancer. ... TNB-585 is a bispecific T cell-engager being evaluated for the treatment of metastatic
More from news
Approximately 69 fully matching, plus 307 partially matching documents found.
Latest Intelligence
-
Unlocking the potential of precision medicine in oncology
continuum of targeted therapies now available to prostate cancer patients, including PARP inhibitors. ... Similarly, DRD testing in late stage prostate cancer is needed to identify patients who could potentially benefit from PARP inhibition.
-
Why digital is the solution to the healthcare crisis
Be it treatment for cancer, aches and pains, unusual lumps, headaches – the general malay that you would visit your doctor or hospital for consultation and treatment. ... Nudge behaviour, such as timely reminders for breast or prostate cancer screening,
-
The human connection: how to achieve emotive creativity in pharma
your patients a disservice while you’re at it). We’ve been acutely aware of this balancing act in our own work; a recent film we worked on for prostate cancer ... With this as our starting point, we introduced messaging about the importance of
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell lung cancer, PSMA in prostate cancer and CLDN18.2 and MUC17 in gastric or ... T cells only become activated and proliferate, with the goal of staying
-
Surviving cancer: a new era for patients
This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... In European patients, the average five-year relative survival rate was 83% for melanoma, 83% for prostate cancer, 82% for breast cancer and 57% for colon
More from intelligence
Approximately 1 fully matching, plus 53 partially matching documents found.
Latest appointments
-
Virtual agency The Difference Collective makes new hires to senior team
Levy, a published author of research into the needs of men with advanced prostate cancer, also brings over ten years of experience in the healthcare sector to the team.
-
Dendreon appoints new R&D lead
urologists who are uniquely positioned to deliver long-term care to men with prostate cancer. ... stage prostate cancer, with the hope of curing more men of the disease.”.
-
Astellas bolsters oncology clinical development leadership
breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.
-
Astellas promotes John Demaree
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice
-
MDxHealth creates new global commercial team
MDxHealth has created a new global commercial team to drive the launch of SelectMDx, its new prostate cancer test. ... the commercialisation of a molecular diagnostic test for prostate cancer across Europe.”.
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
A Lucid Thirsty Thursday D&I Special
In a month focused on raising awareness of Black history and prostate cancer, Che’s life experiences are pertinent and valuable. ... These include growing up as the only Black kid in his school, socialising with groups with opposing views to his own,
-
Men’s Health Awareness Month
According to research , men are more likely to die six years earlier than women due to :. - Mental health. - Prostate cancer. - Testicular cancer. What are the causes for that?
-
Black community representation in clinical trials
This Black History Month, we discuss the black representation in clinical trials and the effects COVID-19 has had on the black community. Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical
-
WHITE PAPER: Why do men die younger?
10. This includes:. Supporting research efforts for male-specific diseases such as prostate and testicular cancer.
-
EPG Health launches Medthority, a medical website personalised for doctors and tailored for pharma
These are self-contained, disease and condition specific educational resources for topics including stroke prevention, transplantation and prostate cancer.
More from PMHub
Approximately 6 fully matching, plus 20 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
PMHub
Life Healthcare Communications
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
